

BODY FAT DISTRIBUTION CHANGES DURING WEIGHT LOSS DETERMINED BY DUAL-ENERGY X-RAY ABSORPTIOMETRIC ANDROID/GYNOID RATIOS INDEXES OF ABDOMINAL OBESITY

Shubeska Stratrova S¹, Efremovska Lj², Janicevic Ivanovska D³, Vesna Velikj Stefanovska⁴

¹University Clinic of Endocrinology, Diabetes and Metabolic disorders, Medical Faculty, Skopje, R. Macedonia

²Department of Physiology and Anthropology, Medical faculty, Skopje, R. Macedonia

³University Clinic of Clinical biochemistry, Skopje, Faculty of Medical Sciences, University Goce Delchev, R. Macedonia

⁴Institute of Epidemiology and Biostatistics, Faculty of Medicine, Ss Cyril and Methodius of Skopje, R. Macedonia

Abstract

The effect of weight loss on body fat distribution was examined through central obesity indexes (COI), which are android/gynoid tissue and fat mass ratios determined by dual-energy X-ray absorptiometry (DXA) and their relationship with lipid profile changes.

The following parameters were determined before and after weight loss in 4 postmenopausal women: body mass index (BMI), body weight (BW), android (A) and gynoid (G) tissue mass (TM) and fat mass (FM) and their % with DXA, and their ratios as indexes of abdominal fat distribution COI₁ (A/G-TM), COI₂ (A/G-FM), COI₃ (A/G-TMfat%) and COI₄ (A/G-FM%), as well as lipid profile: total cholesterol (C), triglycerides (TG), HDL-C, LDL-C, LDL/HDL-C, C/HDL-C and TG/HDL-C.

BW of 63±1.4 kg and BMI value of 29±0.65 kg/m² before the weight loss lowered to 49±1.6 kg and normal BMI 22.62±0.74 kg/m² (p<0.012). COI₁ value decreased significantly from 0.5±0.01 to normal value 0.42±0.02 (p<0.003). COI₂ value decreased significantly from 0.45±0.02 to normal value 0.34±0.02 (p<0.0004). COI₃ value decrease from 0.95±0.026 to 0.74±0.012 was significant (p<0.0009) and COI₄ value decrease from 0.95±0.01 to 0.74±0.02 was also significant (p<0.0001). Atherogenic indexes TG/HDL-C, LDL/HDL-C and C/HDL lowered significantly after the weight loss (p<0.002; p<0.03 and p<0.05). TG, C and LDL values lowered significantly (p<0.001; p<0.01; p<0.01).

It was confirmed that DXA indexes of central, abdominal obesity COI₁ and COI₂ were increased in overweight women before the weight loss and lowered significantly after the weight loss to normal values, indicating that normal BMI and BW reached after the weight loss were associated with normalized body fat distribution, and significant reduction of the atherogenic lipid profile indicating reduced atherogenic risk.

Key words: DXA indexes, abdominal obesity, weight loss, lipid profile.

INTRODUCTION

Central obesity can be an early warning sign of a condition called metabolic syndrome. The core abnormality of Metabolic Syndrome is increased body weight, and particularly central, abdominal obesity as well as dyslipidemia. Dyslipidemic profile, and increased C/HDL-C, LDL/HDL-C and TG/HDL-C ratios values are especially important components and indicators of cardiovascular risk. Their predictive value is greater than the isolated parameters.

Obesity and central body fat distribution are known risk factors for cardiovascular and metabolic diseases. Excess abdominal fat is referred to as android obesity and it is an important, independent risk factor for disease, which is associated with increased risk for cardiovascular disease. Android obesity, which is predominantly visceral, intra-abdominal, is more predictive of adipose-related comorbidities than gynecoid obesity, which has a relatively peripheral (gluteal) distribution.

Shubeska S. (1) discovered with DXA that BMI increase in healthy women was associated with a more pronounced abdominal body fat distribution (2), indicating a substantially higher risk for development of metabolic and cardiovascular complications. DXA also measures and monitors body composition changes in obese patients undergoing weight loss. It monitors how much fat was lost in different body compartments. Some relationship ratios between central (android, abdominal) regional tissue and FM to peripheral gynoid regional parts of the body in patients with Cushing's syndrome (CS) were discovered as diagnostic criteria of visceral, abdominal obesity in patients with CS (4, 5). DXA indexes of central, abdominal obesity android/gynoid TM and FM and android/gynoid TMfat% and FM% ratios discovered extreme central body fat distribution in CS, differentiated them significantly from healthy women with normal BMI and obese with the same BMI as CS, and these are discovered DXA indexes of abdominal, central obesity that should be used as DXA indexes of extreme central, abdominal obesity in CS and in non CS obese women. They are indicators of abdominal obesity (5, 6). The assessment of abdominal fat accumulation, especially in postmenopausal (postM) women, is an important screening tool for the prevention of the obesity associated health complications (7). DXA measurements of fat distribution are very useful in studies related to obesity-associated disease risk.

The aim of this study was to investigate body composition and body fat distribution with DXA indexes of central, abdominal obesity, android/gynoid TM and android/gynoid FM ratios and their TMfat% and FM% ratios as well as lipid values and atherogenic indexes and their changes after weight loss with consequent normal BMI. It was important to discover weight loss influence on body fat distribution and lipid metabolism.

MATERIAL AND METHODS

The examinees were four postmenopausal women with mean BMI 29 ± 0.65 kg/m² that lowered to normal values of 22.62 ± 0.74 kg/m² and BW 63 ± 1.4 kg that lowered to 49 ± 1.6 kg after the weight loss ($p<0.012$). Android (A) and gynoid (G) fat mass (FM) and its percentage (FM%), tissue mass (TM) and TM fat percentage (TMfat%) were determined with DXA before and after weight loss and the changes of the DXA indexes of abdominal body fat distribution COI₁ (A/G-TM), COI₂ (A/G-FM) and COI₃ (A/G-TMfat%) and COI₄ (A/G-FM%).

Total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), LDL/HDL-C, TC/HDL-C and TG/HDL-C were also determined.

Body height was measured by a wall stadiometer in barefoot subjects with head in a horizontal Frankfurt plane to the nearest 0.1 cm. BW was measured by a digital scale while wearing light clothing and it was estimated in kilograms (kg). BMI was calculated with the following formula: weight (kg)/height (m²). DXA assessment was performed with DXA System Lunar DPX-NT, which uses encore 10.x Windows-XP Professional OS computers. The entire body of the subject was scanned. During DXA scan, the subject was in a supine position while the x-ray scanner performed a series of transverse scans, measured at 1-cm intervals from the top of the head to the bottom of the toes. The DXA machine was calibrated daily in accordance with the manufacturer's guidelines to ensure adequate quality control. The system enabled simultaneous assessment of total and regional body composition and body fat distribution.

Statistical analyses were performed using the statistical software program SPSS for Windows, version 22,0. Quantitative series were analyzed with measures of central tendency (average, median), as well as with dispersion measures (standard deviation). Values of different parameters before and after the weight loss were tested by T-test for dependant samples. P values $<0,05$ were considered to be statistically significant.

RESULTS

Table 1. COI₁, COI₂, COI₃ and COI₄ values before and after weight loss

Parameters	Before weight lost	After weight lost	T-test for dependant samples
COI ₁ (A/G TM)	$0,5 \pm 0,01$	$0,42\pm 0,02$	t-test= 8,1847; df=3; p=0,0038*
COI ₂ (A/G FM)	$0,45\pm 0,02$	$0,34\pm 0,02$	t-test=17,298; df=3; p=0,0004*

COI ₃ (A/G TMfat%)	0.95±0.026	0.74±0.012	t-test=13,237; df=3; p=0,0009*
COI ₄ (A/G FM%)	0.95±0.01	0.74±0.02	t-test=22,968; df=3; p=0,00018*

*Significant for p<0,05

COI₁ - A/G-TM (android/gynoid tissue mass ratio)

COI₂ - A/G-FM (android/gynoid fat mass ratio)

COI₃- A/G-TMfat% (android/gynoid tissue mass fat percent ratio)

COI₄ - A/G-FM% (android/gynoid fat mass percent ratio)

COI₁, COI₂, COI₃ as well as COI₄ were highly significantly lower after the weight loss.

Table 2. Android and Gynoid TM, TMfat%, FM and FM% values before and after weight loss

Parameters	Before weight loss	After weight loss	T-test for dependant samples
Android TM (gr)	5415,75±74,37	3692,50±188,39	t-test= 23,999; df=3; p=0,0002*
Gynoid TM (gr)	10768,75±48,71	8817,50±309,67	t-test= 12,833; df=3; p=0,0011*
Android FM (gr)	2634,25±106,45	1141,75±33,01	t-test=90,427; df=3; p=0,000003*
Gynoid FM (gr)	5841,25±84,12	3352,75±125,13	t-test= 24,29; df=3; p=0,0001*
Android TMfat%	49.83±0.83	29.78±1.51	t-test=48,043; df=3; p=0,00002*
Gynoid TMfat%	52.53±2.26	40.03±1.69	t-test=34,893; df=3; p=0,00005*
Android FM%	49.13±1.01	28.13±1.45	t-test=21,000; df=3; p=0,00008*
Gynoid FM%	51.68±1.3	37.85±1.43	t-test=13,825; df=3; p=0,00009*

*Significant for p<0,05

TM - tissue mass

FM - fat mass

TMfat% - tissue mass fat percent

FM% - fat mass percent

A and G TM and FM values and their percentages were highly significantly different and the values of android and gynoid TMfat% and FM% showed the highest significance of the difference between the values before and after weight loss.

Table 3. Lipid levels and atherogenic indexes before and after weight loss

Lipid levels	Before weight loss	After weight loss	T-test for dependant samples
Triglycerides	1.23±0.05	0.78±0.11	t-test=10,678; df=3; p=0,0017*
Total Cholesterol	6.55±0.1	5.2±0.55	t-test=4,666; df=3; p=0,0185*
HDL cholesterol	1.61±0.07	1.61±0.08	t-test=-0,0524; df=3; p=0,9615
LDL cholesterol	4.3±0.08	3.17±0.52	t-test=4,6152; df=3; p=0,0191*
LDL/HDL-C	2.68±0.09	1.98±0.39	t-test=43,5712; df=3; p=0,0375*
C/HDL-C	4.1±0.26	3.24±0.47	t-test=-3,0225; df=3; p=0,0566
TG/HDL-C	0.77±0.07	0.49±0.08	t-test=10,0948; df=3; p=0,0021*

C - cholesterol; HDL - high density lipoprotein; LDL - low density lipoprotein

TG - triglycerides

Total cholesterol levels were significantly lower after the weight loss ($p < 0.01$) as well as LDL cholesterol levels ($p < 0.01$), LDL/HDL-C ratio ($p < 0.03$), TC/HDL-C ratio ($p < 0.05$). Triglycerides had higher significance of the difference between the values before and after weight loss ($p < 0.001$) and TG/HDL-C ($p < 0.002$).

DISCUSSION

The main characteristic of the metabolic syndrome is the increased body weight, and particularly central, abdominal obesity as well as dyslipidemia. People with metabolic syndrome have elevated blood pressure, high triglycerides, low levels of HDL cholesterol and insulin resistance. This combination of factors creates an especially high risk for stroke, coronary artery disease, cardiovascular disease-related mortality and type 2 diabetes.

Obese subjects have higher percentage of FM from the total body mass compared to non obese. Obesity and central body fat distribution are known risk factors for cardiovascular and metabolic diseases.

Menopause is a high-risk time for weight gain. PostMP women have significantly more fat, a more central fat distribution, and less lean tissue mass than premenopausal (preMP) women (8, 9). Menopause-related central body fat accumulation potentially contributes to the increased incidence of disease observed in postMP, compared with preMP women (10, 11). The subjects in this study were postmenopausal.

There is growing evidence that intra-abdominal adipose tissue (IAAT), rather than total body fat, is a risk factor for metabolic conditions associated with obesity. For this reason the evaluation of IAAT is clinically important (12). Because of that, effective methods for assessing visceral fat are important to investigate its role in the increased health risks in obesity (13). There is an increased interest in the evaluation of various methods for assessment of body composition and fat distribution (14). DXA body composition and fat distribution assessment may be useful in studies related to obesity-associated risks (15, 16).

DXA enables precise, accurate body composition and body fat distribution assessment. In a previous study, in 2011 Shubeska S. (1) discovered with DXA that BMI increase in healthy women was associated with a more pronounced abdominal, visceral fat distribution (1, 2). Also, BMI reduction, the quantity of fat loss, body composition and body fat distribution changes are monitored with DXA in obese patients undergoing weight loss. It monitors how much fat was lost during weight loss.

DXA method determines absolute (kg) and relative (%) total, bone, lean and fat body mass and separately their regional values on arms, legs, head and trunk. Body composition, including fat mass, body fat distribution and muscle mass, gradually change with aging, even if the body weight and BMI remain unchanged. LBM decreases significantly, while fat mass increases and is preferentially stored in abdominal tissues (17, 18, 19). Trunk FM increase is a result of dominant android, abdominal FM increase indicating increased risk for metabolic complications (6). Body fat distribution is simply determined with DXA by the relationship of the regional (segmental) fat compartments. The relationship of the predominantly central, android, abdominal FM and tissue mass (TM) and the gynoid (peripheral FM and TM) is an indicator of the central, abdominal obesity (4). DXA is fast becoming the new gold standard because it provides a higher degree of precision in only one measurement and has the ability to show exactly where fat is distributed throughout the body. It is a very reliable method and its results are extremely repeatable; in addition, the method is safe and presents little burden to the subject.

It was found that low weight, independent of menopausal status, leads to the typical gynoid pattern of fat distribution while excess weight and obesity result in an android pattern of fat distribution in pre- and postMP women (15). By measuring body composition, a person's health status can be more accurately assessed and the effects of both dietary and physical activity programs better directed. Since a scale measures "body weight", which includes fat, muscles, bones and organs, it can't specifically tell how much fat had been lost, and the only way to measure actual fat loss is to measure "body composition", not body weight in weight loss programs. DXA can precisely monitor how much fat is lost during weight loss (20, 21).

Total body analysis with DXA is the ideal way for the serious athlete, the person monitoring or beginning a program of exercise or weight loss, or anyone curious or concerned about their health to receive a quick, painless, accurate and confidential assessment of their body's composition. Also, measurements of body composition and body fat distribution with DXA have provided a research tool to study the metabolic effects of aging, obesity, and various wasting conditions.

Changes in body composition during weight loss programs might have a significant effect on long-term results and sensitive DXA indexes of abdominal, central obesity are needed, because of lack of normal reference data, which is an issue that is currently being addressed.

CS patients are discovered gold standard of extreme central, visceral, abdominal body fat distribution. DXA indexes of central, abdominal body fat distribution in Cushing's (CS) could also be used as a gold standard for abdominal obesity in non CS. They were discovered as a diagnostic criterion of extreme central, visceral obesity in CS and abdominal obese controls (CO), non Cushing's (non CS) with the same BMI as CS. Shubeska-Stratrova S. (2015) (4), showed that the

ratios of insignificantly different central and peripheral regional parts of the body, precisely differentiated the patients with CS and non CS obese, and confirmed central body fat distribution in CS (16, 21, 22). In that study it was found with DXA that A/G TM (0.67 ± 0.1) and A/G FM ratios (0.72 ± 0.2) in CS were significantly higher compared to CO (0.48 ± 0.05) ($p<0.0001$) and (0.46 ± 0.09) ($p<0.001$) (4). They differentiated CS and CO with very high significance and discovered extreme central body fat distribution in CS, and could be used as DXA indexes of extreme central, abdominal obesity in CS and non CS abdominal obese women. DXA indexes of central body fat distribution in CS could also be a gold standard and diagnostic criterion of extreme central, abdominal fat distribution in different types of obesity (non CS).

Cut-off points of the following indexes confirmed extreme central, abdominal obesity: COI₁ (A/G-TM) ratio higher than 0.54 and COI₂ (A/G-FM) ratio higher than 0.51 (4, 16, 23). Normal cut-off point values were also discovered, A/G-TM value lower than 0.51 and A/G-FM value lower than 0.38 (23). In this study COI₁ value decreased significantly from 0.5 ± 0.01 to normal value 0.42 ± 0.02 ($p<0.003$). COI₂ value decreased significantly from 0.45 ± 0.02 to normal value 0.34 ± 0.02 ($p<0.0004$). COI₃ value decrease from 0.95 ± 0.026 to 0.74 ± 0.012 was significant ($p<0.0009$) and COI₄ value decrease from 0.95 ± 0.01 to 0.74 ± 0.02 was also highly significant ($p<0.0001$).

Shubeska-Stratrova S. (2019) (23), discovered that COI₃ was significantly higher in CS 1.05 ± 0.15 compared to 0.67 ± 0.15 in healthy non obese women with normal BMI ($p<0.0001$) with normal cut off point value lower than 0.9. COI₃ and COI₄ also lowered significantly after the weight loss ($p<0.0009$; $p<0.0001$). Significant reduction in these indexes of central obesity after the weight loss confirmed reduction of abdominal obesity and normalized body fat distribution.

An increase in total cholesterol concentration, and specifically LDL cholesterol (an atherogenic lipid marker), and reduced HDL cholesterol concentration are correlated with numerous risk factors, including the components of the metabolic syndrome, and probably involve independent risk (24, 25, 26). Low-density lipoprotein (LDL) cholesterol concentration has been the prime index of cardiovascular disease risk and the main target for therapy.

In an attempt to optimize the predictive capacity of the lipid profile, several lipoprotein ratios or “atherogenic indices” have been defined. These ratios can provide information on risk factors difficult to quantify by routine analyses and could be a better mirror of the metabolic and clinical interactions between lipid fractions. Total/high-density lipoprotein (HDL) cholesterol, TG/HDL-C and LDL/HDL cholesterol ratios are risk indicators with greater predictive value than isolated parameters used independently, particularly LDL. Total cholesterol/HDL ratio is considered a more sensitive and specific index of cardiovascular risk than total cholesterol (27,28, 29,30).

In this study lipid levels in the examined overweight subject also showed higher risk for development of metabolic complications. LDL/HDL-C and TC/HDL-C significantly lowered after the weight lost and BMI normalization. Atherogenic indexes TG/HDL-C, LDL/HDL-C and C/HDL lowered significantly after the weight loss ($p<0.002$; $p<0.03$ and $p<0.05$). TG, C and LDL values lowered significantly ($p<0.001$; $p<0.01$; $p<0.01$).

BW and BMI reduction to normal levels was associated with significant decrease of indexes of central body fat distribution android/gynoid TM and FM to normal values, as well as significant reduction of atherogenic lipid indexes indicating reduced atherogenic risk.

CONCLUSION

It can be concluded that the increased values of the relationships between regional central, abdominal and peripheral gynoid parts of the body COI_1 , COI_2 , COI_3 and COI_4 before the weight loss confirmed abdominal obesity with dyslipidemic profile indicating higher cardiovascular risk in a DXA examined overweight women. Their significant reduction to normal levels after the weight loss confirmed reduced abdominal body fat distribution and consecutive normalized body composition and body fat distribution, confirming the importance of determining these DXA indexes as diagnostic criteria of abdominal obesity.

Significant reduction in these indexes of central obesity after the weight loss confirming reduction of abdominal obesity and normalized body fat distribution showed that body weight reduction in overweight subjects and especially in obese subjects is important in order to improve body composition and body fat distribution and minimize the cardiometabolic profile and risk. These results confirmed that DXA measurements of body composition and body fat distribution are very useful in studies related to obesity-associated disease risk. This study confirmed that COI_1 and COI_2 indexes are valuable diagnostic procedure parameters of abdominal obesity and obesity associated health risks. COI_3 and COI_4 are also useful DXA indexes in body fat distribution assessment.

REFERENCES

1. Shubeska Stratrova S. Densitometric to anthropometric indexes of visceral obesity relations. J Antropol Society Serbia (Novi Sad). 2011; 46:49-58.
2. Shubeska Startrova S. Dual-energy x-ray absorptiometry assessment of the body composition in obese women. J Anthropol Society Serbia (Novi Sad). 2009, 44:455-461.

3. Shubeska Stratrova S, Janicevic Ivanovska D. Body fat distribution and lipid profile changes after weight loss – a case report. *Knowledge-Int J*. June 2019; 31(4):1071-1076.
4. Shubeska Stratrova S, Snezana Markovik Temelkova, Goran Petrovski. Dual-energy X-ray absorptiometry (DXA) assessment of body composition and body fat distribution in Cushing's women. *Mac Med Review*. 2015; 69(2):86-93.
5. Shubeska Stratrova S, Todorovska L. Android/legs and legs/trunk indexes determined with dual-energy x-ray absorptiometry in Cushing's and non Cushing's obese women. *Arch Pub Health*. 2017; 9(2):18-25.
6. Shubeska Stratrova S, Todorovska L, Efremovska Lj, Gligorovska JP. Evaluation of central obesity in Cushing's and non Cushing's women with dual-energy x-ray absorptiometry. *Physioacta*. 2017; 11(2):7-14.
7. Shubeska Stratrova S. Dual-energy x-ray absorptiometry assessment of the body composition and body fat distribution in pre- and postmenopausal women. *J Antropol Society Serbia*. Novi Sad, 2010; 45:199-206.
8. Shubeska Stratrova S. Dual-energy x-ray absorptiometry assessment of the body composition and body fat distribution in pre- and postmenopausal women. *J Antropol Society Serbia (Novi Sad)*, 2010; 45:199-206.
9. Svendsen OL, Hassager C, Christiansen C. Age- and menopause-associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry. *Metabolism*. 1995; 44(3):369-73.
10. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Menopause-related changes in body fat distribution. *Ann N Y Acad Sci*. 2000; 904:502-6.
11. Garaulet M, Pérez-Llamas F, Baraza JC, Garcia-Prieto MD, Fardy PS. Body fat distribution in pre-and post-menopausal women: metabolic and anthropometric variables. *J Nutr Health Aging*. 2002; 6(2):123-6.
12. Bouchard C, Bray GA, Hubbard VS. Basic and clinical aspects of regional fat distribution. *Am J Clin Nutr* 1990; 52(5): 946-50.
13. Snijder MB, Visser M, Dekker JM. The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry. *Int J Obes Relat Metab Disord*. 2002; 26(7):984-93.
14. Kim JS, Yoo SM, Kim KN, Lee SY. Comparison of DEXA and CT for truncal obesity in adult women related to metabolic complications. *J Korean Acad Fam Med*. 2007 Sep; 28(9):675-681.

15. Kamel EG, McNeill G, Han TS, Smith FW, Avenell A, Davidson L, Tothill P. Measurement of abdominal fat by magnetic resonance imaging, dual-energy X-ray absorptiometry and anthropometry in non-obese men and women. *Int J Obes Relat Metab Disord.* 1999; 23(7):686-92.
16. Brownbill RA & Ilich JZ. Measuring body composition in overweight individuals by dual energy x-ray absorptiometry. *BMC Medical Imaging* 2005; 5:1.
17. Jensen MD, Kanaley JA, Reed JE, Sheedy PF. Measurements of abdominal and visceral fat with computed tomography and dual-energy x-ray absorptiometry. *Am J Clin Nutr.* 1995; 61(2):274-8.
18. Svendsen OL, Hassager C, Bergmann I, Christiansen C. Measurement of abdominal and intra-abdominal fat in post menopausal women by dual energy X-ray absorptiometry and anthropometry: comparison with computerised tomography. *Int J Obes Relat Metab Disord* 1993; 17(1):45-51.
19. Haarbo J, Gotfredsen A, Hassager C, Christiansen C. Validation of body composition by dual energy X-ray absorptiometry (DEXA). *Clin Physiol.* 1991; 11(4):331-341.
20. Wallner SJ, Luschnigg N, Schnedl WJ, Lahousen T, Sudi K. Body fat distribution of overweight females with a history of weight cycling. *Int J Obes Relat Metab Disord.* 2004; 28(9):1143-8.
21. Shubeska Stratrova S, Dimitrovski C, Todorovska L, Stefanovska Balabanova G. Evaluation of the body composition in female Cushings. *J of the Anthropol Society of Serbia.* Novi Sad 2008, 43:440-447.
22. Hendel HW, Gotfredsen A, Andersen T. Body composition during weight loss in obese patients estimated by dual energy X-ray absorptiometry and by total body potassium. *Int J Obes Relat Metab Disord.* 1996; 20(12):1111-1119.
23. Shubeska Stratrova S, Janicevic Ivanovska D. Estimated central obesity index – worthwhile screening test procedure of abdominal obesity. *Knowledge – Int J.* 2019; 34(4):903-909.
24. Ascaso J, González Santos P, Hernández Mijares A, et al. Management of dyslipidemia in the metabolic syndrome. Recommendations of the Spanish HDL Forum. *Am J Cardiovasc Drugs.* 2007; 7:39–58.
25. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. *Ann Intern Med.* 1994; 121:641–647.
26. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Usefulness of the total cholesterol to high-density lipoprotein cholesterol ratio in predicting angiographic coronary artery disease in women. *Am J Cardiol.* 1991; 68:1646–1650.
27. Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. *JAMA.* 2007; 298:776–785.
28. Nam BH, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. *Am J Cardiol.* 2006; 97:372–375.

29. Mounier-Vehier C, Stephan D, Aboyans V, et al. Groupe vasculaire (SFC-Societe francaise de medecine vasculaires. The best of vascular medicine in 2006. *Arch Mal Coeur Vaiss.* 2007; 100:47–55.
30. Natarajan S, Glick H, Criqui M, Horowitz D, Lipsitz SR, Kinosian B. Cholesterol measures to identify and treat individuals at risk for coronary heart disease. *Am J Prev Med.* 2003; 25:50–57.

Conflict of Interest: None declared